Alveron\nPharma, a newly incorporated company established by Okklo Life Sciences BV and\nSanquinnovate (part of Sanquin), is pleased to announce the closing of a EUR\n6.5M Series A financing round led by Thuja together with Waterman Ventures and\nOost NL. This investment allows Alveron Pharma to select a lead compound,\nconduct non-clinical studies, and complete a first clinical study to demonstrate\nsafety and obtain a first clinical readout.<\/p>\n\n\n\n
Alveron\nPharma will focus on a unique class of cyclodextrin-based drugs, that have the\nability to promote blood coagulation without inducing it in the absence of\nbleeding. Alveron\u2019s first target is to reverse the effects of anticoagulants.\nAnticoagulants (\u201cblood thinners\u201d) are widely prescribed to patients with\nincreased thromboembolic risk. While effective in preventing thrombosis, these\ndrugs also inhibit blood coagulation when this is needed urgently, e.g. in\npatients who suffer a major bleed or in case of emergency surgery.\nAnticoagulant related bleedings are not uncommon, and may be serious, and\ndifficult to treat since no or only selective reversal agents are available.\nAlveron\u2019s cyclodextrins are unique in the sense that they restore coagulation\nindependent of the type of anticoagulant used. Sales of selective reversal\nagents have been estimated at around $2 billion per annum.<\/p>\n\n\n\n
Ben\nNichols, CEO of Alveron Pharma: \u201cThere is a clear unmet clinical need for a\nuniversal anti-coagulant reversal agent, and the early pre-clinical data for\nAlveron\u2019s unique cyclodextrin compounds are compelling. Having recently taken a\nnew class of coagulant into clinical trials, I am thrilled to be joining the\nfounders of this business, Stephan\nPeters (who conceived the original idea, CSO) and Alex Zwiers (COO), with their\nexpertise on cyclodextrins, and coagulation expert at Sanquin, Joost\nMeijers (Chairman of the Scientific\nAdvisory Board). Alex was also involved in the development of the world\u2019s first\ncyclodextrin-based medicine, Bridion\u00ae.\u201d <\/p>\n\n\n\n
\u201cMultiple\nfactors come together in this investment that are highly attractive\u201d, says\nMichel Briejer of Thuja, who led this transaction. \u201cA highly experienced and\nknowledgeable team, a promising set of drug leads, and a reputable partner in\nthe field of blood, Sanquin. We are extremely pleased to be part of this\nventure and are confident that Alveron will create success for doctors and\npatients alike.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
Alveron Pharma, a newly incorporated company established by Okklo Life Sciences BV and Sanquinnovate (part of Sanquin), is pleased to announce the closing of a EUR 6.5M Series A financing round led by Thuja together with Waterman Ventures and Oost NL. This investment allows Alveron Pharma to select a lead compound, conduct non-clinical studies, and […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-13691","post","type-post","status-publish","format-standard","hentry","category-innovatieklimaat"],"acf":[],"yoast_head":"\n